Articles On Botanix Pharmaceuticals (ASX:BOT)

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy takes the position that the stock market’s recent winners will remain winners. Note that there is a big difference between mome...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Botanix Pharmaceuticals (ASX: BOT) Finishes its $13.5 million placement to accelerate its US commercial activities and to increase revenue turnaround The funds raised are for the commercial launch of Sofpironium Bromide gel, and the plac...

Two ASX cannabis shares aren't joining in the broader market rally today. During the Tuesday lunch hour, the All Ordinaries Index (ASX: XAO) is up 0.5%. But cannabis stocks Little Green Pharma Ltd (ASX: LGP) and Botanix Pharmaceuticals Lt...

ASX health sector falls in line with broader markets on macroeconomic factors and global geopolitical tensions Health imaging stock Volpara announces fourth consecutive quarter of operating cashflow Several ASX healthcare names with positi...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The ASX200 closed the day down half a per cent. As far as the sector performances, healthcare was the clear leader, picking up a per cent and financials just scraped into positive territory. It was a big day for Strike Energy (STX) a...

Botanix Pharmaceuticals’ (BOT) application to use sofpironium bromide gel to treat primary axillary hyperhidrosis has been knocked back by the US FDA A complete FDA review details key issues centred around the need for instructions to us...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. The benchmark index is currently down 0.5% to 7,042.6 points. Four ASX shares that are falling more than most today this week are lis...

US FDA requested Botanix to change its instructions paper Antisense says ATL1102 could be effective in muscular dystrophy Actinogen changes Phase 2b design to reduce cost and time to initial results   Botanix plunges after receiving FDA f...

Stockhead’s Top 10 at shortly-before-11-ish, written through a red haze of blazing, sweary anger this morning because the guy who lives across the street has apparently got his leafblower back from having it repaired – after “someone” might...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price has returned from its trading halt and crashed deep into the red. In morning trade, the cannabis-focused ASX dermatology share is down a massive 36% to 11.5 cents. What's going on with...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create uncertainty Fitch Ratings Agency downgraded the credit rating of Ramsay Health Care (ASX:RHC) to BBB- from BBB Botanix Pharmaceuticals expects...

Cannabis stocks are rebounding, catching short sellers off guard Next signpost for weed investors is the Section 280E of the US IRS tax code We take a look at the best performing weed stocks in last couple of weeks   Having been mauled fo...

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price hit a 52-week high of 21 cents this morning before giving back its gains and dropping into the red. When the ASX cannabis stock hit that level, it meant it was up a massive 160% since...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

New chief executive has experience executing clinical studies Dr Thurn was formerly part of the TGA’s Drug Safety Evaluation Branch Progress continues to be made on MND and canine cancer trials   PharmAust is strengthening its management...

PharmAust (PAA) appoints Dr Michael Thurn as its newest CEO, effective September 1 The company reports he has extensive experience in drug discovery, regulation and clinical trials Dr Roger Aston will remain as Chair, but transition i...

Botanix Pharmaceuticals (ASX: BOT) has announced that its chief operating officer has been appointed as its chief executive officer.

Botanix Pharmaceuticals (BOT) appoints Dr Howie McKibbon as its newest CEO Dr McKibbon was previously Chief Operating Officer at the company He has more than 25 years of experience in the pharmaceutical industry and has led the launch...

Futures predict the ASX will open lower to finish the week, triggered by tech shares losing momentum on Wall Street and leading the market to also close lower. A highly anticipated speech by the US Federal Reserve chairman on the state o...

Local shares set to open sharply lower on Friday Wall Street tumbled by over 1pc overnight as tech momentum faded Betashares says buy ETF for AI exposure   The ASX is set to open much lower this morning as the momentum on US tech stocks d...

Mastercard says no to weed transactions New York is where weed is happening Jeremy Buckingham pulls a stunt at NSW Parliament   Here’s a quick snapshot of cannabis news making headlines over the past week: Mastercard has told banks to sto...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Botanix Pharmaceuticals (BOT) completes a $12.5 million placement and executes a buyout agreement for milestones and royalty payments for Sofpironium Bromide gel The company issues 104,166,667 new fully paid ordinary shares at 12 cents e...

Botanix Pharmaceuticals has secured commitments from investors to raise up to $12.5 million via an institutional placement to fund the buyout of financial obligations owed to another company.

Botanix Pharmaceuticals (BOT) raises $12.5 million through an institutional placement Funds will be used to extinguish future milestone and royalty payments related to Sofpironium Bromide The placement price of 12 cents per share repr...

Clinical validation study confirms efficacy of INOVIQ’s SubB2M/CA15-3 test for breast cancer Ramsay releases several announcements this week including possible sale of joint Asian venture Mach 7 expects significant cash collections in Q4...

The weed industry has slumped as it faces several headwinds But new data suggests the industry will grow significantly over the next decade We take a look at how the ASX weed stocks have performed over the past week   As we head into the...

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

OncoSil gets Ethics committee approval Starpharma’s  nasal spray VIRALEZE granted approval in Malaysia Botanix Pharmaceuticals strikes deal in Korea   Medical device OncoSil Medical (ASX:OSL) rose 8% this morning after the Ethics committe...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

A handful of ASX biotechs are entering their crucial stages of development Promising outlooks for PharmAxis, Botanix Pharma, and Paragon Care   Pharmaxis could surge if FDA application successful Broker Taylor Collison sees an Outperform...

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has secured commitments to raise $10 million that will be used to progress its lead development program.

ASX 200 benchmark closes 0.5% higher, thanks to Energy surge.  XTX All Technology index has the batteries back in, up 1.26% for the day. Liontown farm-in huge news for E-I-E-I-Olympia Metals.   Local markets opened higher this morning (+0...

Botanix Pharmaceuticals’ (BOT) lead product, Sofpironium Bromide, passes an FDA mid-cycle review The FDA detected no safety issues and no risk management issues or board requirements in the review of the Botanix product BOT says it wi...

Botanix Pharmaceuticals chief operating officer Dr Howie McKibbon believes Aussie Investors are comfortable backing early-stage, high-risk companies which is good for biotechs. When pitching an investment opportunity focused on a new drug...

The ASX 200 was unchanged  The ASX XEC slips 0.38% 8 out of 11 sectors were higher lead by Information Technology   The ASX 200 was unchanged today and the ASX XEC was down 0.38%.  The index has lost 0.98% for the last five days, but sit...

The co-founder of Botanix Pharmaceuticals says early interest from big industry players like Pfizer for the company’s gel aimed at treating excessive sweating was giving him confidence ahead of a key review. 

Tim Boreham is one of Australia’s best-known small-cap share analysts and business journalists. He has more than 30 years of experience writing for major business publications.   After a rickety year dominated by the interest rate rises we...

Botanix Pharmaceuticals (BOT) receives confirmation from the US FDA that its new drug application (NDA) for its sofpironium bromide product is formally in reviewThe FDA confirms it identified no filing review issues in the company’s NDA, an...

Botanix Pharmaceuticals (BOT) has raised $5.96 million through a placement and share purchase plan (SPP)The company today reported its SPP, which closed last week, raised $960,000 — roughly a third of the $3 million soughtMeanwhile, the der...

Two more US states join the 19 that already allow legal recreational cannabis use ECS Botanics’ Victorian medical cannabis facility is safe from flooding in the state, so far Cann looks to commercialise its Satipharm CBD capsules for over-...

Botanix Pharmaceuticals (BOT) is raising up to $8 million through a private placement and a share purchase planBotanix received commitments from Antares Capital, a new institutional investor with knowledge of the company’s pipeline of asset...

Nuheara secures FDA over-the-counter approval for its new affordable hearing aid Nitro Software rejects unsolicited Potentia takeover bid ‘cos Alludo has a better one Edtech company Schrole nabs Rio Tinto deal to support its Simandou iron...

Aussie market delivers a rock-solid mediocre effort Koba Resources hits the jackpot by hammering some tent pegs into the dirt Thank the heavens, not much has changed since lunchtime   It’s not been a record-breaker by any stretch of the i...